Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ludivine Morisset"'
Autor:
Petra ter Brugge, Sarah C. Moser, Ivan Bièche, Petra Kristel, Sabrina Ibadioune, Alexandre Eeckhoutte, Roebi de Bruijn, Eline van der Burg, Catrin Lutz, Stefano Annunziato, Julian de Ruiter, Julien Masliah Planchon, Sophie Vacher, Laura Courtois, Rania El-Botty, Ahmed Dahmani, Elodie Montaudon, Ludivine Morisset, Laura Sourd, Léa Huguet, Heloise Derrien, Fariba Nemati, Sophie Chateau-Joubert, Thibaut Larcher, Anne Salomon, Didier Decaudin, Fabien Reyal, Florence Coussy, Tatiana Popova, Jelle Wesseling, Marc-Henri Stern, Jos Jonkers, Elisabetta Marangoni
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Homologous recombination deficiency is linked with platinum-based chemotherapy response in triple-negative breast cancer (TNBC) but methods to clinically identify these patients are lacking. Here, using patient-derived xenografts of TNBC the authors
Externí odkaz:
https://doaj.org/article/45c67b1c1e0a4a2998d04e87b0b265a7
Autor:
Julien Jacquemetton, Loay Kassem, Coralie Poulard, Ahmed Dahmani, Ludmilla De Plater, Elodie Montaudon, Laura Sourd, Ludivine Morisset, Rania El Botty, Sophie Chateau-Joubert, Sophie Vacher, Ivan Bièche, Isabelle Treilleux, Olivier Trédan, Elisabetta Marangoni, Muriel Le Romancer
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Abstract Background Endocrine therapies targeting estrogen signaling have significantly improved breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to those therapies. Aside from genomic signaling, estrogen triggers
Externí odkaz:
https://doaj.org/article/b4f002221c8e4979bfc49c690736c595
Autor:
Elodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, Ludivine Morisset, Rania El Botty, Léa Huguet, Ahmed Dahmani, Pierre Painsec, Fariba Nemati, Sophie Vacher, Walid Chemlali, Julien Masliah-Planchon, Sophie Château-Joubert, Camilla Rega, Mariana Ferreira Leal, Nikiana Simigdala, Sunil Pancholi, Ricardo Ribas, André Nicolas, Didier Meseure, Anne Vincent-Salomon, Cécile Reyes, Audrey Rapinat, David Gentien, Thibaut Larcher, Mylène Bohec, Sylvain Baulande, Virginie Bernard, Didier Decaudin, Florence Coussy, Muriel Le Romancer, Guillaume Dutertre, Zakia Tariq, Paul Cottu, Keltouma Driouch, Ivan Bièche, Lesley-Ann Martin, Elisabetta Marangoni
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Identifying novel therapies for the treatment of CDK4/6 inhibitor-resistant patients is of great importance. Here, the authors demonstrate that PLK1 inhibition is a potential therapeutic target in CCND1-driven and in RB-positive Palbociclib-resistant
Externí odkaz:
https://doaj.org/article/cbbadef41cb14a1b91639138a1f60fcb
Autor:
Muriel Le Romancer, Ahmed Dahmani, Ludivine Morisset, Coralie Poulard, Ivan Bièche, Loay Kassem, Isabelle Treilleux, Julien Jacquemetton, Sophie Vacher, Laura Sourd, Rania El Botty, Olivier Tredan, Ludmilla de Plater, Elodie Montaudon, Elisabetta Marangoni, Sophie Chateau-Joubert
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Breast Cancer Research
Breast Cancer Research, 2021, 23 (1), pp.57. ⟨10.1186/s13058-021-01433-8⟩
Breast Cancer Research, Vol 23, Iss 1, Pp 1-15 (2021)
Breast Cancer Research
Breast Cancer Research, 2021, 23 (1), pp.57. ⟨10.1186/s13058-021-01433-8⟩
Background Endocrine therapies targeting estrogen signaling have significantly improved breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to those therapies. Aside from genomic signaling, estrogen triggers non-geno
Autor:
Zakia Tariq, Sunil Pancholi, Nikiana Simigdala, Thibaut Larcher, Virginie Bernard, Mariana Ferreira Leal, Sophie Château-Joubert, Camilla Rega, Muriel Le Romancer, Fariba Nemati, Didier Decaudin, Ludivine Morisset, Anne Vincent-Salomon, Rania El Botty, Elisabetta Marangoni, Ahmed Dahmani, Cécile Reyes, Walid Chemlali, Audrey Rapinat, Ricardo Ribas, Guillaume Dutertre, Didier Meseure, Lesley-Ann Martin, Paul Cottu, Elodie Montaudon, Julien Masliah-Planchon, Sophie Vacher, Keltouma Driouch, Joanna Nikitorowicz-Buniak, Laura Sourd, Léa Huguet, Florence Coussy, Mylène Bohec, André Nicolas, Sylvain Baulande, Ivan Bièche, Pierre Painsec, David Gentien
Publikováno v:
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11, ⟨10.1038/s41467-020-17697-1⟩
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Nature Communications, 2020, 11, ⟨10.1038/s41467-020-17697-1⟩
Nature Communications, Nature Publishing Group, 2020, 11, ⟨10.1038/s41467-020-17697-1⟩
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Nature Communications, 2020, 11, ⟨10.1038/s41467-020-17697-1⟩
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing and gene expression analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b64c51e1e6ab2dfb4230eb3283b81c
https://hal.inrae.fr/hal-02933439/document
https://hal.inrae.fr/hal-02933439/document
Autor:
Muriel Le Romancer, Julien Jacquemetton, Loay Kassem, Coralie Poulard, Ahmed Dahmani, Ludmilla De PLATER, Elodie Montaudon, Laura Sourd, Ludivine Morisset, Rania El Botty, Sophie Chateau-Joubert, Sophie Vacher, Ivan Bieche, Isabelle Treilleux, Olivier Trédan, Elisabetta Marangoni
Background Endocrine therapies targeting oestrogen signalling have significantly improved breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to those therapies. Aside from genomic signalling, oestrogen triggers non-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ffd15f46dbda36fcf384b930430aee8
https://doi.org/10.21203/rs.3.rs-54785/v1
https://doi.org/10.21203/rs.3.rs-54785/v1
Autor:
Scott Lovell, Ludivine Morisset, Robert Clarke, Daniel Conole, Elisabetta Marangoni, Angélica Santiago-Gómez, Aida Sarmiento-Castro, D Alferez, Sacha J Howell, Katherine Spence, Bertram Kohler, Edward W. Tate, Tiago Moreira, Chiara Chiodo, Bruno M Simões, Andrew H. Sims, Sebastiano Andò, Marilena Lanzino, Rachel Eyre
Publikováno v:
M Simoes, B, Santiago-Gómez, A, Chiodo, C, Moreira, T, Conole, D, Lovell, S, Alferez-Castro, D, Eyre, R, Spence, K, Sarmiento Castro, A, Kohler, B, Morisset, L, Lanzino, M, Ando, S, Marangoni, E, Sims, A H, Tate, E, Howell, S & Clarke, R 2020, ' Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer ', Oncogene, vol. 39, no. 25, pp. 4896–4908 . https://doi.org/10.1038/s41388-020-1335-z
Oncogene
Oncogene
Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy. Multiple mechanisms of endocrine therapy resistance have been identified, including cancer stem-like cell (CSC) activity. Here we investigate SFX-01, a stabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a29ad6ff20d67551f7e765115198540c
https://doi.org/10.1038/s41388-020-1335-z
https://doi.org/10.1038/s41388-020-1335-z
Autor:
Petra ter Brugge, Laetitia Fuhrmann, Fabien Reyal, Rania El-Botty, Thibaut Larcher, Laura Sourd, Sophie Château-Joubert, Agnès Noël, Jean-Luc Servely, Léa Huguet, Ivan Bièche, Pierre Foidart, Jos Jonkers, Philippe La Rosa, Pierre Painsec, Sophie Leboucher, Ludivine Morisset, Fariba Nemati, Georges Lucotte, Elodie Montaudon, Didier Decaudin, Christopher R. Mueller, Florence Coussy, Ahmed Dahmani, Marc-Henri Stern, Marie-France Poupon, Nor Eddine Sounni, Sophie Vacher, Adrien Briaux, Yves Pommier, Anne Vincent Salomon, Elisabetta Marangoni, Cécile Reyes, Tatiana Popova
Publikováno v:
Science Translational Medicine
Science Translational Medicine, American Association for the Advancement of Science, 2020, 12 (531), pp.eaax2625. ⟨10.1126/scitranslmed.aax2625⟩
Science Translational Medicine, 2020, 12 (531), pp.eaax2625. ⟨10.1126/scitranslmed.aax2625⟩
Science Translational Medicine 531 (12), eaax2625. (2020)
Sci Transl Med
Science Translational Medicine, American Association for the Advancement of Science, 2020, 12 (531), pp.eaax2625. ⟨10.1126/scitranslmed.aax2625⟩
Science Translational Medicine, 2020, 12 (531), pp.eaax2625. ⟨10.1126/scitranslmed.aax2625⟩
Science Translational Medicine 531 (12), eaax2625. (2020)
Sci Transl Med
Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand breaks (DSBs) during replication, which are repaired by homologous recombination (HR). Triple-negative breast cancer (TNBC) could be eligible for TOP1 inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::628ae50cedf84171a8f9b149d01b34d7
https://hal.archives-ouvertes.fr/hal-02508765
https://hal.archives-ouvertes.fr/hal-02508765
Autor:
Ahmed Dahmani, Adrien Briaux, L. De Koning, Ivan Bièche, Samia Melaabi, C. Gu, Marion Lavigne, Elodie Montaudon, Sophie Vacher, R. El Botty, Léa Huguet, Laura Sourd, Ludivine Morisset, Pierre Painsec, Laetitia Fuhrmann, A. Vincent Salomon, Elisabetta Marangoni, S. Chateau-Joubert, Thibaut Larcher, Florence Coussy
Publikováno v:
Journal of Hematology and Oncology
Journal of Hematology and Oncology, BioMed Central, 2020, 13 (1), ⟨10.1186/s13045-020-0846-y⟩
Journal of Hematology and Oncology 1 (13), . (2020)
Journal of Hematology and Oncology, 2020, 13 (1), ⟨10.1186/s13045-020-0846-y⟩
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Journal of Hematology and Oncology, BioMed Central, 2020, 13 (1), ⟨10.1186/s13045-020-0846-y⟩
Journal of Hematology and Oncology 1 (13), . (2020)
Journal of Hematology and Oncology, 2020, 13 (1), ⟨10.1186/s13045-020-0846-y⟩
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5eb82233a830089db4f9ce445fba42b
https://hal.archives-ouvertes.fr/hal-02508763
https://hal.archives-ouvertes.fr/hal-02508763
Autor:
Cécile Laurent, Gaëlle Pierron, Marion Lavigne, Pierre Painsec, Ivan Bièche, Elisabetta Marangoni, Cécile Reyes, Ahmed Dahmani, Bérengère Ouine, David Gentien, Leanne De Koning, Laura Sourd, Elodie Montaudon, Anne Vincent-Salomon, Ludivine Morisset, Florence Coussy, Samia Melaabi, Franck Assayag, Thibaut Larcher, Sylvain Baulande, Elodie Girard, Céline Callens, Léa Huguet, Sophie Chateau-Joubert, Virginie Bernard, Véronique Diéras, Jean-Luc Servely, Rania El Botty, Anais Boulai, Sophie Vacher
Publikováno v:
International Journal of Cancer
International Journal of Cancer, Wiley, 2019, ⟨10.1002/ijc.32266⟩
International Journal of Cancer, Wiley, 2019, ⟨10.1002/ijc.32266⟩
Triple-negative breast cancer (TNBC) represents 10% of all breast cancers and is a very heterogeneous disease. Globally, women with TNBC have a poor prognosis, and the development of effective targeted therapies remains a real challenge. Patient-deri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d10c672c83def0adf5c66b0eede7a5
https://hal.archives-ouvertes.fr/hal-02093370
https://hal.archives-ouvertes.fr/hal-02093370